Objective

2

To explore the possible mechanism of

Jianpi Yiqi Shexue Formula

（健脾益气摄血方， JYSF） in the treatment of primary immune thrombocytopenia （ITP）.

Methods

2

Thirty BALB/c mice were randomly divided into control group， model group， prednisone group， JYSF moderate-dose and high-dose groups， with six mice in each group. Except for the normal group， mice were injected with guinea pig anti-mouse platelet serum （GP-APS） to establish the ITP model. On the 8th day after successful modelling， the control group and the model group were given 0.1 ml/10 g of normal saline by gavage； the predinsone group was given 0.1 ml/10 g of prednisone solution with a 2 mg/ml concentration by gavage； and the JYSF moderate-dose and high-dose groups were given 4.1 mg/g and 8.2 mg/g JYSF granules by gavage， respectively.All the groups were administered once daily for eight days. The content of secretory immunoglobulin A （sIgA） in mouse intestinal mucus was detected by immunoturbidimetry； P53 protein expression in mouse mesenteric lymph node lymphocytes was detected by immunohistochemistry； the apoptosis rate of the mesenteric lymph node lymphocytes was detected by TUNEL； and the change of lymphocyte cycle in mesenteric lymph node was detected by flow cytometry.

Results

2

Compared to the normal group， the model group significantly decreased the content of sIgA in intestinal mucus， increased the expression of P53 protein in mesenteric lymph node lymphocytes， and increased the lymphocyte apoptosis rate （

P

＜0.01）. Compared to the model group， the other three groups significantly increased the sIgA content （

P

＜

0.01）， as well as decreased the expression of p53 protein and the lymphocyte apoptosis rate （

P

＜0.05 or

P

＜0.01）. When compared among the prednisone group and the JYSF groups， it was found that the sIgA content was highest in the JYSF high-dose group （

P

＜0.01）， and the lymphocyte apoptosis rate was highest in the JYSF moderate-dose group （

P

＜0.01）. There was no significant difference among the groups in lymphocyte cycle （

P

＞0.05）.

Conclusion

2

The mechanism of JYSF in the treatment of ITP may be related to regulating the content of sIgA in the intestinal mucus and the expression of P53 protein in mesenteric lymph node lymphocytes， as well as reducing the lymphocyte apoptosis rate and improving the intestinal immune function； and there may be a certain dose-response relationship.